論文

SMCラボラトリーズは、製薬企業や研究機関のご要望に沿った試験をデザインするコンサルティング型の
CROとして世界的に⾼い評価をいただいています。
特にMASH/NASHの研究分野では、当社独自のSTAM™マウスを用いた薬効評価試験サービスを提供しており、
STAM™マウスを用いた研究成果は雑誌や学会などで多く公表されております。

Publications

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

No.75

2022

Cell metab.,

“MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity” (Cell Metab., DOI: 10.1016/j.cmet.2022.10.007., 2022)
VIEW ARTICLE bug

No.74

2022

Cell Death & Disease.,

“Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH” (Cell Death & Disease., DOI: 10.1038/s41419-022-05452-x., 2022)
VIEW ARTICLE bug

No.74

2022

bioRxiv.,

“Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced biological response modifier β-glucan (BRMG)” (bioRxiv., DOI: https://doi.org/10.1101/2022.11.17.516628, 2022)
VIEW ARTICLE bug

No.72

2022

J Clin Exp Hepatol.,

“Hepatoprotective effects of Aureobasidium pullulans derived β 1,3-1,6 glucans in a murine model of non-alcoholic steatohepatitis - Journal of Clinical and Experimental Hepatology” (J Clin Exp Hepatol., DOI:https://doi.org/10.1016/j.jceh.2022.06.008., 2022)
VIEW ARTICLE bug

No.71

2022

Cell metab.,

“Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia” (Cell Metab. DOI: 10.1016/j.cmet.2022.05.004., 2022)
VIEW ARTICLE bug

No.70

2022

PLoS One.,

“A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo” (PLoS One., DOI: 10.1371/journal.pone.0263828., 2022)
VIEW ARTICLE bug

No.69

2022

PLoS One.,

“Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model”(PLoS One., DOI: 10.1371/journal.pone.0261310., 2022)
VIEW ARTICLE bug

No.68

2022

Cells.,

“Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non Alcoholic Steatohepatitis” (Cells., DOI: 10.3390/cells11040720., 2022)
VIEW ARTICLE bug

No.67

2022

PLoS One.,

“Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosisbut not NASH progression” (PLoS One., DOI: 10.1371/journal.pone.0263828., 2022)
VIEW ARTICLE bug

No.66

2022

Mol Metab.,

“Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function” (Mol Metab., doi: 10.1016/j.molmet.2022.101487., 2022)
VIEW ARTICLE bug